Table 1.

Non-randomised, uncontrolled clinical trials. OCEBM level of evidence 2b

Authors	Year published	Country	Phase	No. of patients	Age	MS duration (y)	Type of MS	EDSS (baseline)	Follow-up (y)	EDSS (final)	PFS (y)	Death due to aHSCT
Intermediate-intensity, myeloablative
Nash et al	2017	USA	II	24	37	4.9	RRMS	4.5	5.2	62% improved, 21% stable	5 y: 91.3%	0
Moore et al	2019	Australia	II	35	37	6.9	RRMS (57%), SPMS (43%)	6	3	44% improved	3 y: 88% (RRMS)	0
Shevchenko et al	2012	Russia	II	95	34.5	–	RRMS (44%), SPMS (37%), PPMS (16%), PRMS (3%)	3.5	3.8	80% improved or stable	5 y: 92% early; 5 y: 73% conventional/salvage	0
Saiz et al	2004	Spain	I	14	32.3	14.9	RRMS (36%), SPMS (64%)	6	3	28% improved, 57% stable	3 y: 85.7%	0
Saccardi et al	2005	Italy	II	19	36	12	SPMS (79%), RRMS (21%)	6.5	3	58% improved, 26% stable	6 y: 95%	0
Capello et al	2005	Italy	II	21	36	12	SPMS (81%), RRMS (19%)	6.5	2	95% improved or stable	–	0
Hamerschalk et al	2010	Brazil	I	20	42	5.3	SPMS (86.7%), PPMS (9.5%), RRMS (4.8%)	6.5	3	44.4% worse	–	3
Kozák et al	2001	Czech Republic	I	10	39	–	SPMS	6.5	0.8	40% improved, 50% stable	–	0
Mancardi et al	2001	Italy	I	10	35.5	12	SPMS	6.5	1.3	100% improved or stable	–	0
Fassas et al	1997	Greece	I/II	15	–	10	PMS	6	0.5	47% improved, 47% stable	–	0
High intensity
Atkins et al	2016	Canada	II	24	34	5.8	RRMS (50%) SPMS (50%)	–	6.7	70% stable	–	1
Nash et al	2003	USA	I	26	41	7	SPMS (65%), PPMS (31%), RRMS (4%)	7	12	8% improved, 54% stable	–	1
Samijn et al	2006	The Netherlands	I	14	35	5	SPMS	6	3	14% improved, 21% stable	–	0
Burt et al	2003	USA	I/II	21	40	7	SPMS (66%), PRMS (28%), RRMS (4%)	7	2.6 (EDSS > 6), 1 (EDSS < 6)	4% improved, 19% stable	–	0